| The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG … JK Mooi, P Wirapati, R Asher, CK Lee, P Savas, TJ Price, A Townsend, ... Annals of Oncology 29 (11), 2240-2246, 2018 | 154 | 2018 |
| Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability DS Williams, MJ Bird, RN Jorissen, YL Yu, F Walker, HH Zhang, EC Nice, ... PloS one 5 (12), e16012, 2010 | 101 | 2010 |
| Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer AJ Weickhardt, DS Williams, CK Lee, F Chionh, J Simes, C Murone, ... British journal of cancer 113 (1), 37-45, 2015 | 76 | 2015 |
| Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes DS Williams, D Mouradov, RN Jorissen, MR Newman, E Amini, ... Gut 68 (3), 465-474, 2019 | 71 | 2019 |
| Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis … AJ Weickhardt, D Williams, C Lee, J Simes, C Murone, K Wilson, ... Journal of Clinical Oncology 29 (15_suppl), 3531-3531, 2011 | 69 | 2011 |
| A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer F Day, A Muranyi, S Singh, K Shanmugam, D Williams, D Byrne, K Pham, ... Targeted oncology 10, 99-109, 2015 | 63 | 2015 |
| Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity M Dávalos-Salas, MK Montgomery, CM Reehorst, R Nightingale, I Ng, ... Nature communications 10 (1), 5291, 2019 | 54 | 2019 |
| Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma S Arulananda, B Thapa, M Walkiewicz, GV Zapparoli, DS Williams, ... Journal of Thoracic Oncology 13 (10), 1588-1594, 2018 | 50 | 2018 |
| Villin expression is frequently lost in poorly differentiated colon cancer D Arango, S Al-Obaidi, DS Williams, H Dopeso, R Mazzolini, G Corner, ... The American journal of pathology 180 (4), 1509-1521, 2012 | 47 | 2012 |
| Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B‐Raf HH Zhang, F Walker, S Kiflemariam, RH Whitehead, D Williams, ... International journal of cancer 125 (2), 297-307, 2009 | 46 | 2009 |
| Intestinal epithelial-specific PTEN inactivation results in tumor formation DS Byun, N Ahmed, S Nasser, J Shin, S Al-Obaidi, S Goel, GA Corner, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 301 (5 …, 2011 | 41 | 2011 |
| Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver LF Lau, DS Williams, ST Lee, AM Scott, C Christophi, V Muralidharan Annals of surgical oncology 21, 2420-2428, 2014 | 34 | 2014 |
| Host IL11 Signaling Suppresses CD4+ T cell–Mediated Antitumor Responses to Colon Cancer in Mice J Huynh, D Baloyan, D Chisanga, W Shi, M O'Brien, S Afshar-Sterle, ... Cancer immunology research 9 (7), 735-747, 2021 | 29 | 2021 |
| Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous … DS Williams, D Mouradov, MR Newman, E Amini, DK Nickless, CG Fang, ... Modern Pathology 33 (7), 1420-1432, 2020 | 29 | 2020 |
| Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer DS Williams, D Mouradov, C Browne, M Palmieri, MJ Elliott, R Nightingale, ... Modern Pathology 33 (3), 483-495, 2020 | 24 | 2020 |
| Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets DK Lau, D Mouradov, W Wasenang, IY Luk, CM Scott, DS Williams, ... IScience 21, 624-637, 2019 | 19 | 2019 |
| Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK DK Lau, IY Luk, LJ Jenkins, A Martin, DS Williams, KL Schoffer, F Chionh, ... Molecular cancer therapeutics 20 (4), 704-715, 2021 | 18 | 2021 |
| EHF is essential for epidermal and colonic epithelial homeostasis, and suppresses Apc-initiated colonic tumorigenesis CM Reehorst, R Nightingale, IY Luk, L Jenkins, F Koentgen, DS Williams, ... Development 148 (12), dev199542, 2021 | 17 | 2021 |
| BCL-XL is an actionable target for treatment of malignant pleural mesothelioma S Arulananda, M O’Brien, M Evangelista, TJ Harris, NS Steinohrt, ... Cell death discovery 6 (1), 114, 2020 | 17 | 2020 |
| Possible use of synthetic surface-active agents for the preparation of tumour cell nuclei ME Hodes, CG Palmer, DS Williams Nature 182 (4634), 529-530, 1958 | 17 | 1958 |
